VRTX Stock Summary and Trading Ideas (Vertex Pharmaceuticals | NASDAQ:VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.

As of December 29, 2025, VRTX stock price declined to $459.78 with 593,357 million shares trading.

VRTX has a beta of 0.15, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.01 to the broad based SPY ETF.

VRTX has a market cap of $116.65 billion. This is considered a Large Cap stock.

Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.80 earnings per share. This beat revenue expectation by $24 million and exceeded earnings estimates by $.45.

In the last 3 years, VRTX traded as high as $519.88 and as low as $282.21.

The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

VRTX has underperformed the market in the last year with a return of +12.0%, while SPY returned +15.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VRTX shares. However, VRTX has outperformed the market in the last 3 month and 2 week periods, returning +19.2% and +1.7%, while SPY returned +4.2% and +1.2%, respectively. This indicates VRTX has been having a stronger performance recently.

VRTX support price is $455.93 and resistance is $469.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.